Alivus Life Sciences Q1 FY'27 Earnings Call Transcript Released
Alivus Life Sciences reported Q1 FY'27 revenues of ₹640 crore, up 6.4% YoY, driven by 26.5% growth in non-GPL business. Gross margins improved to 60.2% and EBITDA margins to 36.6%. The company guides for 10-12% revenue growth in FY'27, skewed towards H2, and expects to maintain EBITDA margins of 30-32%. Solapur facility operational in early Q3 FY'27.
The announcement provides an update on the company's quarterly performance and future guidance, which are key factors for investors. The positive financial results and forward-looking statements are likely to influence investor sentiment and stock performance.
The company reported positive revenue growth, improved profitability with higher gross and EBITDA margins, and provided a confident growth outlook for the fiscal year. The strong performance in the non-GPL segment and strategic progress on facilities further contribute to the positive sentiment.
Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) has released the transcript of its earnings call held on July 31, 2026, for the first quarter ended June 30, 2026. The transcript is available on the company's website and has been filed with the stock exchanges. During the call, Dr. Yasir Rawjee, MD & CEO, highlighted a positive start to Q1 FY'27 with healthy revenue growth and improving profitability. The company reported revenues of ₹640 crore, a 6.4% year-on-year growth, despite a significant decline in the GPL business. The non-GPL business showed strong growth of 26.5% year-on-year, driven by new product launches and demand. Gross margins improved to 60.2% and EBITDA margins increased to 36.6%, year-on-year. The CDMO business recorded 3.8% year-on-year growth, with expectations of gaining momentum in the second half of the year. Capex for the quarter was ₹85 crore, with an expected total capex of approximately ₹540 crore for FY'27. The company guided for revenue growth of 10% to 12% in FY'27, with growth skewed towards H2 FY'27, and expects to sustain EBITDA margins in the 30% to 32% range. The Solapur facility is expected to be operational in early Q3 of FY'27, and construction of the Taloja R&D center has begun. The company remains debt-free with cash and cash equivalents of ₹880 crore as of June 30, 2026. Management expressed confidence in the company's growth outlook, driven by a robust product pipeline and disciplined execution.
What to do with a filing like this
Alivus Life Sciences Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Alivus Life Sciences Limited. Read the original for the full detail.